Community-acquiredpneumonia


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This article highlights the diagnostics and treatment of community-acquired pneumonia and using of cephalospoins of the second generation, in particular cefuroxime axetil as part of the drug of choice in the treatment of patients with community-acquired pneumonia.

Full Text

Restricted Access

About the authors

Vsevolod V. Skvortsov

Volgograd State Medical University

Email: vskvortsov1@ya.ru
Dr. of Medical sciences, Associate professor at Propaedeutic at Internal Medicine Department

Boleslav N. Levitan

Astrakhan State Medical University

Email: bolev@mail.ru
MD, professor, Head of Faculty Therapy Department

Ellina A. Golieva

Volgograd State Medical University

Email: golieva133@yandex.ru
4th year student of General Medicine Department

Georgii I. Malyakin

Volgograd State Medical University

Email: manuljke@gmail.com
4th year student of General Medicine Department

References

  1. Metlay JP, Fine MJ. Testing strategies in the initial management of patients with community-acquired pneumonia. Ann Intern Med 2013; 138: 109-18.
  2. Syrjala H, Broas M, Suramo I, Ojala A, Lahde S. High-resolution computed tomography for the diagnosis of community-acquired pneumonia. Clin Infect Dis 2008; 27: 358-63.
  3. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC et al. Infectious Diseases Society of America/American Thoracic Society consensus guide- lines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2017; 44 Suppl 2:S27-S72.
  4. Basi SK, Marrie TJ, Huang JQ, Majumdar SR. Patients admitted to hospital with suspected pneumonia and normal chest radiographs: epidemiology, microbiology, and outcomes. Am J Med 2014; 117: 305-11.
  5. American Thoracic Society. Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
  6. Mathers C, Bernard C, and Moesgaard Iburg K. WHO. Global Burden of Disease in 2002:data sources, methods and results 2010. Ref Type: Generic.
  7. Niederman MS. Community-acquired pneumonia: the U.S. perspective. Semin Respir Crit Care Med 2009; 30: 179-88.
  8. WHO/UNICEF. Pneumonia: The forgotten killer of children. 2008. Ref Type: Generic
  9. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 2017; 336: 243-50.
  10. Агафонова О.В., Гриценко Т.А., Богданова Ю.В. и др. Поликлиническая терапия: Учебник / под ред. Д.И. Давыдкина, Ю.В. Щукина. - 2-е изд., перераб. и доп. - М.: ГЭОТАР-Медиа, 2020. - 840с. doi: 10.33029/9704-5545-6-PLT-2020-1-840.
  11. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 2016; 275: 134-41.
  12. Koivula I, Sten M, Makela PH. Risk factors for pneumonia in the elderly. Am J Med 2014; 96: 313-20.
  13. Baik I, Curhan GC, Rimm EB, Bendich A, Willett WC, Fawzi WW. A prospective study of age and lifestyle factors in relation to community-acquired pneumonia in US men and women. Arch Intern Med 2010; 160:3082-8.
  14. Marrie TJ. Community-acquired pneumonia in the elderly. Clin Infect Dis 2010; 31: 1066-78.
  15. Fernandez-Sabe N, Carratala J, Roson B, Dorca J, Verdaguer R, Manresa F, Gudiol F. Community-acquired pneu- monia in very elderly patients: causative organisms, clinical characteristics, and outcomes. Medicine (Baltimore) 2013; 82: 159-69.
  16. Jennings LC, Anderson TP, Beynon KA, Chua A, Laing RT, Werno AM et al. Incidence and characteristics of viral community-acquired pneumonia in adults. Thorax 2008; 63: 42-8.
  17. Johnstone J, Majumdar SR, Fox JD, Marrie TJ. Viral infection in adults hospitalized with community-acquired pneumonia: prevalence, pathogens, and presentation. Chest 2008; 134: 1141-48.
  18. Hayden FG. Rhinovirus and the lower respiratory tract. Rev Med Virol 2014; 14: 17-31.
  19. Marcos MA, Esperatti M, Torres A. Viral pneumonia. Curr Opin Infect Dis 2009; 22: 143-7.
  20. Hageman JC, Uyeki TM, Francis JS, Jernigan DB, Wheeler JG, Bridges CB et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis 2006; 12: 894-9.
  21. Palacios G, Hornig M, Cisterna D, Savji N, Bussetti AV, Kapoor V et al. Streptococcus pneumoniae coinfection is correlated with the severity of H1N1 pandemic influenza. PLoS One 2009; 4: e8540.
  22. Murray RJ, Robinson JO, White JN, Hughes F, Coombs GW, Pearson JC et al. Community-acquired pneumonia due to pandemic A(H1N1)2009 influenzavirus and methicillin resistant Staphylococcus aureus co-infection. PLoS One 2010; 5: e8705.
  23. Goetz MB RDTA. Pyogenic bacterial pneumonia, lung abscess, and Empyema. In Mason RJ MJBVNJ, editor. Murray and Nadel’s Textbook of Respiratory Medicine. 4th edition. Philadelphia, PA: Saunders Elsevier; 2005.
  24. Menendez R, Martinez R, Reyes S, Mensa J, Filella X, Marcos MA et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax 2009; 64: 587-91.
  25. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: 377-82.
  26. Espana PP, Capelastegui A, Quintana JM, Soto A, Gorordo I, Garcia-Urbaneja M et al. A prediction rule to identify allocation of inpatient care in community-acquired pneumonia. Eur Respir J 2003; 21: 695-701.
  27. Liapikou A, Ferrer M, Polverino E, Balasso V, Esperatti M, Piner R et al. Severe Community-Acquired Pneumonia: Validation of the Infectious Diseases Society of America/ American Thoracic Society Guidelines to Predict an Intensive Care Unit Admission. Clin Infect Dis 2009; 48: 377-85.
  28. Визель А., Визель И., Гизатуллина Э. Пневмония у больных ХОБЛ, получающих ингаляционные глюкокортикостероиды. Врач, 2017; 2 (28): 17-23
  29. Лаврова О., Петрова М. Особенности диагностики и лечения внебольничной пневмонии у беременных. Врач, 2018; 8 (29): 8-11. https://doi.org/10.29296/25877305-2018-08-02
  30. Титова О., Кузубова Н., Склярова Д., Барышникова К., Александров А., Половников И. Особенности внебольничной пневмонии у пациентов, госпитализированных в пульмонологическое отделение. Врач, 2019; 10 (30): 43-49 https://doi.org/10.29296/25877305-2019-10-09
  31. Воробьева А., Сапожников В. Значение типа конституции для своевременной диагностики острой пневмонии у детей. Врач, 2020; 2 (31): 12-17 https://doi. org/10.29296/25877305-2020-02-03
  32. Афанасьев Н., Байда А., Батурин В. Оказание помощи больным внебольничной пневмонией в сельских стационарах ставропольского края. Врач, 2019; 3 (30): 73-75 https://doi.org/10.29296/25877305-2019-03-16
  33. Штейнер М., Биктагиров Ю., Белоусова Т. Бронхоскопия в неврологической практике. Врач, 2015; (4): 60-63
  34. Титова О., Кузубова Н., Александров А., Перлей В, Шумилов А. Особенности гемодинамики при внебольничной пневмонии на фоне ХОБЛ. Врач, 2018; 12 (29): 51-54 https://doi.org/10.29296/25877305-2018-12-12
  35. Бородулина Е., Яковлева Е. Диссеминированная форма мелкоклеточного рака легких в практике врача-пульмонолога. Врач, 2019; 4 (30): 65-69 https://doi. org/10.29296/25877305-2019-04-12

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies